| |
Editor-in-Chief
Lajos P. Balogh, PhD
Buffalo, NY
baloghl@prodigy.net
Managing Editor
Alice Landwehr
Tucson, Arizona
nanomedicine@cox.net
Publisher
Kate Williamson
Elsevier Inc.
1600 John F. Kennedy Blvd., Suite 1800
Philadelphia, PA 19103
k.williamson@elsevier.com
ONLINE SUBMISSION
SITE:  http://ees.elsevier.com/nano/
Aims and Scope of the Journal
Nanomedicine: Nanotechnology,
Biology, and Medicine
(Nanomedicine: NBM)
is an international, peer-reviewed
journal. Each issue of
Nanomedicine: NBM
presents theoretical and experimental research results related to nanoscience and nanotechnology in life sciences, including Basic,
Translational, and Clinical research, and commercialization of results. Article formats include Communications, Original Articles, Reviews,
Perspectives, Technical and Commercialization Notes, and Letters to the Editor. In addition, regular features on our website will address
commercialization, funding opportunities, and societal, Public Health, and ethical issues of nanomedicine. We invite authors to submit
original manuscripts in these categories.
General Policies and Instructions for Authors
Authors should provide in the manuscript
only information essential for the discussion of results, and utilize the Supporting Materials file to provide all experimental details
and other non-essential, but useful information.
Article Types
COMMUNICATIONS: Communications are to disseminate
new observations quickly to the scientific community. Length of communications should not exceed 1,200 words (including body text, and
figure legends), maximum 4 figures, and 10 references. Communications enjoy priority in publishing.
ORIGINAL ARTICLES: Full
length articles describe a full account about hypothesis-based research or theory in nanomedicine. Length should not exceed 5,000 words
(including body text, and figure legends), and the article should have no more than 6 figures in the main article. No more than 50 references
should be cited.
SCIENTIFIC REVIEWS: Review articles of selected important topics in nanomedicine research. Length should
not exceed 10,000 words (including body text, and figure legends), and the article should have no more than 15 figures. No more than
150 references should be cited.
PERSPECTIVES IN NANOMEDICINE: Invited articles or brief editorial comments that represent
opinions of recognized leaders in nanomedicine research; length should not exceed 3000 words (including body text, and figure legends),
LETTERS TO THE EDITOR: Letters to the Editor serves the purpose to comment on research published in NNBM, including critical
issues. Letters may not exceed 500 words with maximum 10 references and one illustration and one table.
TECHNICAL AND COMMERCIALIZATION
NOTES: Information regarding new technologies, business issues, commercialization of new products in the field, including Intellectual
Property and patenting, Nanotechnology Law, etc. Length of technical notes should not exceed 1200 words (including body text, and figure
legends), 4 figures, and 10 references.
There are no limitations for length, figures and references in Supporting Information.
. Authors are encouraged to provide only information, which is essential for the discussion of results and utilize supporting information
to describe all experimental details and non-essential, but useful information.
TEMPLATE BASED PUBLISHING: Book Reviews,
Meeting Announcements and Meeting Summaries may be published on the
Journal
website under a different heading and without
typesetting. For Book Review and Meeting Summary proposals, please email the editor directly. For Meeting Announcements, please contact
Kate Williamson.
The
Journal
will provide templates for material that will not receive typesetting. For questions,
please contact Kate Williamson.
Peer Review
All manuscripts will be first evaluated for completeness and adherence
to submission guidelines and will then undergo a peer-review process.
Provisional or final acceptance is based on originality, scientific
accuracy,
relevance, clarity, and topical balance of the
Journal.
A request to submit a revised manuscript
does
not guarantee its acceptance, only
that it will be reconsidered by the editor. Decisions will be
communicated to the corresponding author
by e-mail.
Conflict of Interest
Authors are required to acknowledge all funding sources that supported their
work as well as
all institutional or corporate affiliations of the authors. Each submission
must also include a publishable statement
on the title page disclosing any commercial
associations, current and within the past five years that might pose
a potential, perceived,
or real conflict of interest. These include
grants, patent licensing arrangements, consultancies, stock or other
equity ownership, advisory
board memberships, or payments for
conducting or publicizing the study.
When no competing interests are present, include a statement
on the title page.
The editor asks each reviewer to disclose any competing
interests or to recuse oneself if a competing interest might
interfere
with one's objectivity. For more information, please see Elsevier's Conflict
of Interest and Disclosure
policies.
Ethical Considerations
Nanomedicine: NBM considers research and publication misconduct to be a serious
breach of ethics, and will take such actions as necessary to address such misconduct. Authors should refer to the Committee on Publication
Ethics (COPE) and the International
Committee of Medical Journal Editors for full information. Authors are also encouraged to visit Elsevier's Ethical Guidelines for Journal Publication.
Plagiarism and duplicate submission are serious acts of misconduct.
Plagiarism is defined as unreferenced use of published or unauthorized use of unpublished ideas, and may occur at any stage of planning,
researching, writing, or publication. Plagiarism takes many forms, from 'passing off' another's paper as the author's own paper, to copying
or paraphrasing substantial parts of another's paper (without attribution), to claiming results from research conducted by others. Plagiarism
in all its forms constitutes unethical publishing behavior and is unacceptable. Duplicate submission/publication occurs when two or more
papers, without full cross-reference, share the same hypothesis, data, discussion points, or conclusions.
NIH Public Access Policy
Compliance
To comply with the NIH Public Access Policy, Elsevier will deposit to PubMed Central (PMC) author manuscripts on behalf
of authors reporting NIH funded research. The NIH policy requires that NIH-funded authors submit to PubMed Central (PMC), or have submitted
on their behalf, their peer-reviewed author manuscripts, to appear on PMC no later than 12 months after final publication. Elsevier will
send to PMC the final peer-reviewed manuscript, which was accepted for publication and sent to Elsevier's production department, and
that reflects any author-agreed changes made in response to peer-review comments. Elsevier will authorize the author manuscript's public
access posting 12 months after final publication. Following the deposit by Elsevier, authors will receive further communications from
the NIH with respect to the submission.
Note: Authors must declare their NIH funding (or the other funding bodies listed below) when
completing the copyright transfer form.
Other Funding Body Policies
Elsevier has also worked with the following
funding bodies to ensure that our authors can comply with their policies:
- - Arthritis Research Campaign (UK)
- British
Heart Foundation (UK)
- Cancer Research (UK)
- Chief Scientist Office
- Department of Health (UK)
- Howard
Hughes Medical Institute (US)
- Medical Research Council (UK)
- Wellcome Trust (UK)
For full details on
how these policies are implemented, please see complete information at:
http://www.elsevier.com/wps/find/authorsview.authors/fundingbodyagreements
Requirements for studies involving live human or animal subjects:
For studies that involved human or animal research,
indicate
approval by the institution's human or animal subject review committee
in the Methods section of the manuscript. Include an
additional
statement of the humane care of the animals with animal studies and
a statement of informed consent or exempt classification
by the IRB
with human studies.
Submission of Manuscripts
Manuscripts must be submitted through the Nanomedicine:NBM
online submission and review Web site ( http://ees.elsevier.com/nano ). All manuscripts
submitted to the Journal must be
original and must not have been
previously published elsewhere or currently under consideration by
another publication. In an accompanying
letter, authors should state that the manuscript, or any part of it, is not and will not be submitted elsewhere for publication while
under consideration by
Nanomedicine: NBM. Authors should also suggest the names and contact information of three potential
reviewers for the manuscript.
Manuscript Preparation
Submission items include a cover letter, a list of suggested
reviewers, the
manuscript (including title page, abstract, manuscript text (divided into Background, Methods, Results, and Discussion),
references,
and table/figure legends), tables, and figures. Authors are advised to upload Supplementary Materials (see below) if needed.
Revised manuscripts
should also be accompanied by a unique file (separate from the
cover letter) with responses to reviewers' comments.
The preferred order of files is as follows: cover letter, suggested
reviewers, response to reviews (revised manuscripts only), manuscript
file(s), table(s), figure(s). graphic abstract, supplementary material. Files should be labeled with appropriate and descriptive file
names (e.g., SmithText.doc, Fig1.eps, Table3.doc, Supplementary.pdf). Upload text, tables and graphics as separate files. Do not import
figures or tables into the text document. Please do not upload your text as a PDF, but do upload text-based Supplementary Materials as
a PDF.
Manuscripts must be typed, double-spaced and assembled in
this order: title page, abstract, text, acknowledgments, references,
figure legends, tables and figures.
Leave 1-inch margins on all sides. All manuscripts must conform to
"Uniform Requirements for Manuscripts
Submitted to Biomedical
Journals" ( http://www.icmje.org ).
PERMISSIONS: If any material has been published previously
(figure, tables, etc), provide written permission from the copyright
holder to use such material. Authors are responsible for obtaining
permission and payment of any fees associated with reuse.
TITLE PAGE: The title page should contain these elements: full
title,
all authors' names, academic degrees, and affiliations; short title (not to exceed 50 characters, including
spaces); name and complete
address for corresponding author and address for reprints
if different from correspondence; fax and telephone number and
e-mail address;
conflict of interest statement if applicable; all
sources of support for research; complete manuscript word count (including body text
and figure legends, but excluding abstract, title page and references), number of figures/tables. There is no limit on Supplementary
Material. Manuscript with over-the-limit word counts will be returned to the authors without further review.
ABSTRACT:
The abstract should not exceed 150 words and should
summarize the content of the article. Insert 3 to 5 key words after the abstract.
New! GRAPHICAL ABSTRACTS: Authors are encouraged to submit a graphical abstract for their article. The image should summarize
the contents of the paper in a concise, pictorial form designed to capture the attention of a wide readership and for compilation of
databases. Graphical abstracts should be included as a separate file and submitted with figures; if the graphical abstract appears as
a figure in the manuscript, please note this at the end of the abstract (i.e.: Graphical Abstract: Figure 2).
TEXT: For
Communications and Original Articles, the text should include the headings
Background, Methods, Results, and Discussion. Only essential
data and descriptions shall be provided in the Methods and Results. All experimental details including synthetic and analytical procedures
must be provided as a SUPPLEMENTARY MATERIALS (see details below). All pages must be
numbered. Abbreviations must be parenthetically
notated at first
mention in the text. Each table and figure must be mentioned in the
text. Reports of studies on humans and animals must
indicate that
each study has been approved by an institutional review committee and
the procedures followed are in accordance with institutional
guidelines.
Provide generic rather than trademarked names of drugs.
ACKNOWLEDGMENTS: The acknowledgments section recognizes
substantive contributions of individuals. The Editorial Office
must receive written, signed consent from each person recognized
in the
acknowledgments to be mentioned in the article because
acknowledgment can imply endorsement of data and conclusions. . (See this sample of an Acknowledgement.) Upload each permission separately in the online system. Do not
include statements of funding, conflicts, or other disclosures in the Acknowledgments; these must appear on the title page.
REFERENCES:
Reference format should conform to that set forth in "Uniform
Requirements for Manuscripts Submitted to Biomedical Journals"
( http://www.icmje.org
) and journal abbreviations should conform
to the style used in the
Cumulated Index Medicus. Cite references,
figures,
and tables in numeric order according to the first mention in
the text. Accuracy of reference data is the responsibility of the
author.
Verify all references against
original
sources. "In press"
citations must have been accepted for publication and the
name of
the journal or book publisher must be included. The style of citation
should be as follows:
Journals: authors' last
names and initials; title of article; journal
name; date; volume number, and inclusive pages (list all authors
when six or fewer; when
seven or more, list six and add et al):
1. Graeber GM, Gupta NC, Murray GF. Positron emission tomographic
imaging with fluorodeoxyglucose
is efficacious in evaluating
malignant pulmonary disease. J Thorac Cardiovasc Surg
1999;117:719-27.
2. Lytle BW, Blackstone EH, Loop
FD, Houghtaling PL, Arnold JH,
Akhrass R, et al. Two internal thoracic artery grafts are better than
one. J Thorac Cardiovasc Surg 1999;117:855-72.
Books: authors' last names and initials; chapter title, editor's
name, book title, edition, city, publisher, date, and pages:
1. Mollnes TE. Analysis of in vivo complement activation: In:
Herzenberg LA, Weir DM, Herzenberg LA, Blackwell C, editors.
Weir's handbook
of experimental immunology. Volume 78, 5th
ed. Boston: Blackwell Science; 1997, p. 1-8.
Unpublished data and personal communications
should be cited only
in the text, not as a numbered reference. Authors wishing to cite
unpublished material must have a letter of permission
from the originator
of the communication to do so. This letter should be submitted
with the manuscript.
FIGURES: Figures must
be of professional quality. When possible,
please use first-generation artwork. Figures are
encouraged in electronic format. Figures
may be black and white line art, graphs, halftones
(photographs), or color. Be sure that figures are submitted in .tif or .eps format.
Line art (black lines on a white background) must have a minimum resolution of 1,000 dpi. Combination line art (eg, line art with gray
fill patterns) must be created at 500 dpi. Black and white or color photographs must have a minimum resolution of 300 dpi.
Illustrations
should be saved at the recommended resolution setting
and sized as close to a column width (3 to 4 inches) as possible.
Create figures
in scale with each other to the extent possible. Avoid
background gridlines and other formatting that do not convey information
(eg,
superfluous use of 3-dimensional formatting, background
shadings). Use uniform lettering and sizing of all original artwork.
As a general
rule the lettering on the artwork should have a finished,
printed size of 7 points. Smaller lettering will yield barely legible
text.
Recommended font choices include Arial, Helvetica, or
Symbol. Labeling of multipart figures (eg, A, B, C...) should use capital letters
only and should be done
consistently, preferably using uppercase type (Arial, Helvetica or
Universe, 11 or 12 points) in the lower-right
corner of the figure.
Avoid headings on the figure when possible. Additional information on
preparation of electronic artwork can be
found in the Artwork
Instructions available at http://www.elsevier.com/authors. . For best results,
please follow these
guidelines carefully. There is no charge for publication of color illustrations.
TABLES: Table numbers should be Arabic,
followed by a period
and a brief title. Begin each table on a separate page. Use same size
type as in text where possible. Supply a brief
heading for each
column. Do not use vertical lines between columns. Use horizontal
lines above and below the column headings and at the
bottom of the
table only. Use extra space to delineate sections within the table.
Abbreviations used in the table must be defined in
a footnote to the
table. Indicate footnotes in this order:  .
New! SUPPLEMENTARY MATERIALS: Nanomedicine: NBM accepts supplementary data files to accompany the online article,
allowing authors to support and enhance their papers. Supplementary materials may include experimental details, additional images, background
datasets, video clips, etc. Experiments should be described in such detail that someone trained in the art could repeat the experiment
or measurement. Please provide text-based data as a separate PDF file when submitting your manuscript. All supplementary materials are
subject to peer review, but will not be edited by
Nanomedicine: NBM
. Supplementary materials will not be edited by Nanomedicine:
NBM, and will be posted as provided by the authors. There are no limitations for length, figures and references in Supporting Materials.
VIDEOS: Authors are encouraged to submit videos that give readers a fuller understanding of the article. Supplementary movies or
animation files that supplement a submitted article should be provided in one of the following preferred formats: .mpg, .mov, .avi, or
.gif. All videos are subject to peer review. For more details, please visit http://www.elsevier.com/wps/find/authorsview.authors/movies_animations.
Within a week of acceptance, articles will be available on the www.nanomedjournal.com
and ScienceDirect as Articles in Press, and will be indexed in PubMed/MEDLINE. Articles will then be copyedited and typeset, then compiled
into issues available on the websites.
MEETING INFORMATION (announcements regarding upcoming nanomedicine conferences) and
MEETING SUMMARIES will be posted on www.nanomedjournal.com separately from the scientific contents of the Journal.
OFFPRINTS:
Offprint order forms will be sent to authors
before articles are published. Reprints in quantity must be purchased
from the Publisher.
Updated December 2009
|
| |
|
